<DOC>
	<DOCNO>NCT02501616</DOCNO>
	<brief_summary>This phase 4 , single center , randomize , open-labeled , cross-over design study . The primary objective study compare effect dapagliflozine metformin endothelial function . Subjects randomize initial metformin initial dapagliflozin group maintain initial treatment 8 week . During period , dose dapagliflozin maintain 10mg/day metformin titrate upto 2000 mg/day . After 1 week washout period , 8 week ' cross-over follow .</brief_summary>
	<brief_title>Effect Dapagliflozine Systemic Renal Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Present type 2 diabetes base disease diagnostic criterion describe World Health Organization ( WHO ) 2 . Treated diet exercise alone recent 3 month 3 . Aged 2080 year 4 . HbA1c 7~9 % 5 . This inclusion criterion applies females childbearing potential ( surgically sterilize menarche 1year postmenopause ) . Are breastfeed . Test negative pregnancy time screen base blood serum pregnancy test . Intend become pregnant study . 1 . Previous history IHD brain infarct 2 . Having typical anginal pain atypical chest pain dyspnea 3 . Modification Diet Renal Disease ( MDRD ) estimate GFRâ‰¥60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>